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We found BrAF V600e mutations in 81 % (17 of 
21) pCps by targeted sanger sequencing and in 86 % 
(18 of 21) pCps by IHC. Although there was agreement 
between methods in 95 % (20 out of 21) of cases, inter-
pretation of anti-BrAF V600e staining was challenging 
due to occasional non-specific reactivity. aCp cases were 
selected for the study on the basis of their CTNNB1 
mutation status [6 wild type and 10 mutant (9 T41I, 1 
D32N)]. In all aCps, translocation of β-catenin from 
membrane to cytosol/nucleus was observed, confirming 
the utility of β-catenin translocation as a diagnostic tool. 
Of 16 aCp cases, 14 (88 %) were BrAF wild type by 
sequencing and IHC. We observed BrAF V600e muta-
tion in two aCp cases. This finding was validated by 
careful diagnostic review of morphology and compari-
son with IHC findings. Further validation was obtained 
by sequencing in forward and reverse directions from 
two DNA samples extracted on different occasions. In 
both these specimens, CTNNB1 mutation was also pre-
sent (T41I) (Fig. 1).
sequencing of bulk tumour revealed no relationship 
between CTNNB1 mutation and cytosolic/nuclear accumu-
lation of β-catenin. However, our study did not search for 
mutations at other loci, which could have led to an under-
estimation of the proportion of specimens harbouring 
CTNNB1 mutations. In other studies on FFpe tissue that 
used sanger dideoxy sequencing to search for CTNNB1 
mutation, the rate was also not 100 % [3, 5, 7], suggest-
ing that this method is not sufficiently sensitive to detect 
the presence of a mutation in all samples. In contrast, Bras-
tianos et al. [2] found CTNNB1 mutations in 96 % of aCps 
using mass spectrometric genotyping.
We found BrAF V600e mutations in 81 % of pCps. 
Difficulties interpreting BrAF V600e staining have been 
reported previously and suggest that in specimens with a 
Craniopharyngiomas are epithelial, sellar tumours com-
prising two subtypes: adamantinomatous (aCp) and papil-
lary (pCp). aCps contain mutations in CTNNB1, encoding 
β-catenin: a component of the adherens junction and medi-
ator of Wnt signalling. reported frequency of CTNNB1 
mutations varies widely (16–100 %) [6, 7]. recently, it was 
reported that pCps contain BrAF p.V600e mutations in 
95 % of cases [2] and that CTNNB1 and BrAF mutations 
are mutually exclusive and specific to tumour subtype. We 
examined the relationship between mutation in CTNNB1 
and BrAF and subcellular location of β-catenin in a series 
of 37 craniopharyngiomas. The region of BrAF exon 15 
containing codon 600 was sequenced, as was exon 3 of 
CTNNB1. Immunohistochemistry (IHC) for β-catenin was 
used to examine its subcellular location and an antibody 
specific for the BrAF V600e mutation (clone Ve1) was 
used to complement the sequencing findings in all aCp and 
pCps. Methods are reported in Online resource 1.
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significant amount of epithelium, sequencing may be more 
reliable for determining mutational status of BrAF [1, 8]. 
A mutation in BrAF was found in two aCp cases, both of 
which had a coexisting CTNNB1 mutation, demonstrating 
that although the majority of aCps do not contain BrAF 
mutations, they are not exclusive to pCps and can exist 
with mutations in CTNNB1. In the majority of cases, how-
ever, mutations segregate with tumour subtype: CTNNB1 
in aCps and BrAF in pCps.
While inhibition of the Wnt pathway has proved chal-
lenging and effective inhibitors are still largely in devel-
opment, inhibitors of mutant BrAF have shown efficacy 
as chemotherapeutic agents in the treatment of mela-
noma [4]. The finding that BrAF V600e is mutated in 
the majority of pCps offers the possibility for targeted 
BrAF-inhibitor therapy for patients with this tumour 
type.
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